352 filings
8-K
BXRX
Baudax Bio, Inc.
28 Feb 24
Bankruptcy or Receivership
6:15am
25-NSE
The Nasdaq Stock Market LLC
15 Feb 24
Exchange delisting
8:53am
SC 13G/A
Black Horse Capital LP
14 Feb 24
Baudax Bio / BLACK HORSE CAPITAL ownership change
10:25am
SC 13G/A
BXRX
Baudax Bio, Inc.
6 Feb 24
Baudax Bio / INTRACOASTAL CAPITAL ownership change
11:12am
8-K
BXRX
Baudax Bio, Inc.
12 Dec 23
Other Events
9:52pm
424B3
6e5s0p5c
22 Nov 23
Prospectus supplement
4:58pm
NT 10-Q
uvnaiphbg
15 Nov 23
Notice of late quarterly filing
5:25pm
8-K
erb1aqvz mmz
15 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
andj0k457a4k7ae
25 Oct 23
Changes in Registrant's Certifying Accountant
7:57am
8-K
0dpbvrgl yht
13 Oct 23
Submission of Matters to a Vote of Security Holders
7:00am
3
guglmhjzna8lsxtkcihm
11 Oct 23
Baudax Bio / Natalie McAndrew ownership change
4:47pm
DEFA14A
1gnc1g7 g6
10 Oct 23
Additional proxy soliciting materials
7:00am
8-K
z745gndvlfnsy5b1j20i
6 Oct 23
Departure of Directors or Certain Officers
8:00am
8-K
p2pdy1i
29 Sep 23
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
7:01am
EFFECT
0km04kb7srn
26 Sep 23
Notice of effectiveness
12:15am
EFFECT
t9jm89nxp0plxhhl
26 Sep 23
Notice of effectiveness
12:15am
CORRESP
y2os 9dbqwm06a
21 Sep 23
Correspondence with SEC
12:00am